Vazyme's subsidiary products have obtained medical device registration certificates
Vazyme's wholly-owned subsidiary, Nanjing Vazyme Medical Technology Co., Ltd., recently obtained multiple medical device registration certificates, involving a series of diagnostic reagent products for the nervous system. The company relies on its antibody technology platform to continuously enrich its AD blood test series products and innovatively develop precise detection products for Parkinson's disease and brain injuries, aiming to meet clinical needs in the field of neurological diseases and enhance the diagnosis and treatment service level for brain health and cognitive disorders
According to the Zhitong Finance APP, Vazyme (688105.SH) announced that its wholly-owned subsidiary, Nanjing Vazyme Medical Technology Co., Ltd., has recently obtained multiple "Medical Device Registration Certificates" for several series of diagnostic reagent products for the nervous system in China.
Relying on its own antibody technology platform, the company continues to enrich its AD blood test series products based on global authoritative guidelines, while focusing on key areas in major diseases of the central nervous system. It innovatively develops precise detection and diagnostic products for Parkinson's disease, brain injuries, and other conditions, aiming to address unmet clinical needs in the field of neurological diseases. The company is committed to continuously enhancing the product strength and influence of its chemiluminescence platform, contributing to the improvement of brain health and cognitive disorder diagnosis and treatment services in China, and actively practicing the "Healthy China Strategy." The acquisition of this product registration certificate only represents that the company's related products have obtained market access qualifications in the domestic market
